Compare AbbVie Inc (ABBV) vs Mongodb Inc (MDB) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs Mongodb Inc — how do they compare? AbbVie Inc trades at $253.62 (market cap $449.91B), while Mongodb Inc trades at $355.14 (market cap $29.06B). The key difference: AbbVie Inc is far larger — about 15.5× Mongodb Inc's market cap, and AbbVie Inc pays a 2.72% dividend while Mongodb Inc pays none. Which is the better fit depends on your goals.
| ABBV | MDB | |
|---|---|---|
Market Cap | $449.91B | $29.06B |
Sector | Health | Technology |
52-Week High | $261.07 | $440.25 |
52-Week Low | $184.85 | $201.08 |
Enterprise Value | $513.38B | $26.66B |
Dividend Yield | 2.72% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $252.92, down 0.72% on the day, with strong technical support at $251 and resistance at $258. The stock shows bullish momentum with recent earnings beats and a consensus analyst price target of $266.33. Revenue grew to $61.16B in 2025, though net margins compressed to 5.79%. Key growth drivers include Skyrizi and Rinvoq offsetting Humira declines, supported by positive Phase 2 data for ELAHERE in ovarian cancer (PRNewsWire, 2026-04-12).
Outlook remains positive with immunology portfolio strength and dividend growth, but risks include patent cliffs in the 2030s and high debt levels. Institutional buying and 68% analyst buy ratings suggest confidence, though valuation multiples like P/E of 124.83 warrant caution. Near-term catalysts include Q2 2026 earnings expected at $3.79 EPS.
MongoDB (MDB) trades at $361.32, up 1.81% with a bullish technical trend and strong analyst support. Recent earnings beats and revenue growth to $2.01B in 2025 highlight operational momentum, though profitability remains negative. The stock faces overbought signals near-term but benefits from AI-driven demand and raised 2026 guidance.
Outlook is positive with a $399.05 consensus price target, but risks include high valuation multiples, ongoing losses, and legal scrutiny. Investors should weigh robust growth against profitability challenges and market volatility for balanced exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Mongodb Inc
Founded in 2007, MongoDB is a document-oriented database with nearly 33,000 paying customers and well past 1.5 million free users. MongoDB provides both licenses as well as subscriptions as a service for its NoSQL database. MongoDB's database is compatible with all major programming languages and is capable of being deployed for a variety of use cases.
Read more on MDB →
